Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
A roundup of the first quarter's key oncology drug approvals and rejections.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.